Business

Mass. Movers

Disappointing drug results sink ArQule

Woburn-based ArQule Inc. develops cancer therapies.

Joanne Rathe/Globe Staff/File

Woburn-based ArQule Inc. develops cancer therapies.

An experimental colorectal cancer drug being developed by Woburn’s ArQule Inc. and Japan’s Daiichi Sankyo Co. Ltd. failed to improve patient survival without the cancer worsening. The midstage trial, which enrolled 122 patients, also failed to meet the secondary goal of showing improved response to the drug tivantinib. Friday’s failure is the latest in a series of bad drug-related news. It ended a lung cancer trial in October and an Asian partner halted another trial in August.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com